Do analysts prefer SNGX or KZIA?

Novogen has a consensus target price of $25.80, suggesting a potential upside of 109.59%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation and earnings, SNGX or KZIA?

Soligenix has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Soligenix $120K 46.56 -$11.08M -$1.68 N/A Novogen $30K 677.05 -$13.41M N/A N/A

Is SNGX or KZIA more profitable?

Novogen's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Novogen N/A N/A N/A

Do analysts recommend SNGX or ATOS?

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 780.23%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is SNGX or ATOS more profitable?

Atossa Genetics' return on equity of -84.91% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Atossa Genetics N/A -84.91% -72.36%

Do analysts rate GRDX or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or SNGX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Soligenix N/A -244.73% -131.22%

Do analysts rate SNGX or NEUP?

Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 439.85%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SNGX or NEUP more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts recommend SNGX or CLRB?

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 329.69%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Soligenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is SNGX or CLRB more profitable?

Soligenix's return on equity of -244.73% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% Cellectar Biosciences N/A -349.24% -153.18%

Soligenix (SNGX) Competitors

$0.38 0.00 (-0.13%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.27%)

As of 04:00 AM Eastern

Compare

SNGX vs. KZIA, ATOS, GRDX, NEUP, and CLRB

Should you buy Soligenix stock or one of its competitors? MarketBeat compares Soligenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soligenix include Novogen (KZIA), Atossa Genetics (ATOS), Entero Therapeutics (GRDX), Neuphoria Therapeutics (NEUP), and Cellectar Biosciences (CLRB).

How does Soligenix compare to Novogen?

Soligenix (NASDAQ:SNGX) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Novogen has a consensus target price of $25.80, suggesting a potential upside of 109.59%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Soligenix has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.56	-$11.08M	-$1.68	N/A
Novogen	$30K	677.05	-$13.41M	N/A	N/A

In the previous week, Novogen had 1 more articles in the media than Soligenix. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 equaled Novogen'saverage media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Novogen	Neutral

Soligenix has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Novogen has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novogen's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Novogen	N/A	N/A	N/A

Summary

Novogen beats Soligenix on 9 of the 12 factors compared between the two stocks.

How does Soligenix compare to Atossa Genetics?

Soligenix (NASDAQ:SNGX) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Soligenix has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

In the previous week, Atossa Genetics had 2 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Atossa Genetics and 0 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Atossa Genetics	Neutral

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Soligenix has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.56	-$11.08M	-$1.68	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A

Atossa Genetics' return on equity of -84.91% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Atossa Genetics	N/A	-84.91%	-72.36%

Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 780.23%. Given Atossa Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Atossa Genetics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atossa Genetics beats Soligenix on 8 of the 13 factors compared between the two stocks.

How does Soligenix compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Soligenix (NASDAQ:SNGX) are related small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Entero Therapeutics' return on equity of -49.81% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Soligenix	N/A	-244.73%	-131.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics has higher earnings, but lower revenue than Soligenix. Entero Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	475.06	-$6.39M	-$1.88	N/A
Soligenix	$120K	46.56	-$11.08M	-$1.68	N/A

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Entero Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Soligenix	Neutral

Summary

Soligenix beats Entero Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Soligenix compare to Neuphoria Therapeutics?

Soligenix (NASDAQ:SNGX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Soligenix has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 439.85%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.6% of Soligenix shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 3.1% of Soligenix shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Soligenix. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.56	-$11.08M	-$1.68	N/A
Neuphoria Therapeutics	$15.65M	1.34	-$370K	-$11.06	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Soligenix. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Soligenix. Soligenix's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
Neuphoria Therapeutics	Neutral

Summary

Neuphoria Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Soligenix compare to Cellectar Biosciences?

Soligenix (NASDAQ:SNGX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 3.1% of Soligenix shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Soligenix has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Soligenix's return on equity of -244.73% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Soligenix has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	46.56	-$11.08M	-$1.68	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

In the previous week, Cellectar Biosciences had 4 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Soligenix. Cellectar Biosciences' average media sentiment score of 0.50 beat Soligenix's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Soligenix	Neutral
Cellectar Biosciences	Neutral

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 329.69%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Soligenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Soligenix beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

Get Soligenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNGX vs. The Competition

Export

Metric	Soligenix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.60M	$3.52B	$6.83B	$12.76B
Dividend Yield	N/A	3.77%	2.59%	10.01%
P/E Ratio	-0.22	7.32	279.13	25.53
Price / Sales	46.56	1,289.93	594.51	92.93
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	0.73	16.96	12.93	6.11
Net Income	-$11.08M	-$12.52M	$3.48B	$347.58M
7 Day Performance	4.26%	3.62%	3.38%	4.91%
1 Month Performance	-2.58%	-5.39%	-2.80%	-2.06%
1 Year Performance	-87.35%	49.42%	73.09%	21.03%

Soligenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNGX Soligenix	0.5129 of 5 stars	$0.38 -0.1%	N/A	-87.9%	$5.60M	$120K	N/A	20
KZIA Novogen	1.5407 of 5 stars	$12.69 +3.9%	$25.80 +103.3%	+47.6%	$20.98M	$42K	N/A	12	News Coverage
ATOS Atossa Genetics	1.7937 of 5 stars	$2.41 +2.1%	$20.33 +743.7%	-81.5%	$20.75M	N/A	N/A	8	Upcoming Earnings
GRDX Entero Therapeutics	N/A	$2.99 -5.1%	N/A	N/A	$20.67M	$74.46K	N/A	9	Positive News
NEUP Neuphoria Therapeutics	2.2635 of 5 stars	$3.81 -1.0%	$21.00 +451.2%	-50.0%	$20.59M	-$13.27K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNGX) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soligenix (SNGX) Competitors

SNGX vs. KZIA, ATOS, GRDX, NEUP, and CLRB

How does Soligenix compare to Novogen?

Summary

How does Soligenix compare to Atossa Genetics?

Summary

How does Soligenix compare to Entero Therapeutics?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Summary

How does Soligenix compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soligenix (SNGX) Competitors

SNGX vs. KZIA, ATOS, GRDX, NEUP, and CLRB

How does Soligenix compare to Novogen?

Do analysts prefer SNGX or KZIA?

Which has better valuation and earnings, SNGX or KZIA?

Does the media refer more to SNGX or KZIA?

Which has more volatility and risk, SNGX or KZIA?

Do institutionals & insiders hold more shares of SNGX or KZIA?

Is SNGX or KZIA more profitable?

Summary

How does Soligenix compare to Atossa Genetics?

Which has more volatility and risk, SNGX or ATOS?

Does the media refer more to SNGX or ATOS?

Do institutionals and insiders believe in SNGX or ATOS?

Which has higher earnings & valuation, SNGX or ATOS?

Is SNGX or ATOS more profitable?

Do analysts recommend SNGX or ATOS?

Summary

How does Soligenix compare to Entero Therapeutics?

Is GRDX or SNGX more profitable?

Do analysts rate GRDX or SNGX?

Which has stronger earnings & valuation, GRDX or SNGX?

Do insiders and institutionals have more ownership in GRDX or SNGX?

Which has more risk and volatility, GRDX or SNGX?

Does the media prefer GRDX or SNGX?

Summary

How does Soligenix compare to Neuphoria Therapeutics?

Which has more volatility & risk, SNGX or NEUP?

Do analysts rate SNGX or NEUP?

Do institutionals and insiders have more ownership in SNGX or NEUP?

Which has stronger valuation and earnings, SNGX or NEUP?

Is SNGX or NEUP more profitable?

Does the media refer more to SNGX or NEUP?

Summary

How does Soligenix compare to Cellectar Biosciences?

Do insiders and institutionals have more ownership in SNGX or CLRB?

Which has more volatility & risk, SNGX or CLRB?

Is SNGX or CLRB more profitable?

Which has better earnings and valuation, SNGX or CLRB?

Does the media favor SNGX or CLRB?

Do analysts recommend SNGX or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNGX vs. The Competition

Soligenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools